Trabectedin and Irinotecan Show Promise in Ewing Sarcoma Phase 1/2 Trial

When I first saw the headline about trabectedin and low-dose irinotecan showing promise in targeting the EWS::FLI1 transcription factor for Ewing sarcoma, my initial thought wasn’t just about the science—it was about who this could help right here in our community. As someone who’s spent years covering medical breakthroughs and their real-world ripple effects, I know that a phase 1/2 trial published in Nature Medicine on April 16, 2026, doesn’t just live in abstract journals. It echoes in hospital corridors, influences treatment conversations at kitchen tables, and ultimately shapes hope for families facing this rare but aggressive bone and soft tissue cancer. That’s why, for this deep dive, I’m turning our focus to Seattle, Washington—a city where world-class research meets grounded patient care, and where news like this doesn’t just get reported; it gets lived.

The SARC037 trial, which evaluated trabectedin given as a 1-hour infusion combined with low-dose irinotecan in patients with relapsed or refractory Ewing sarcoma, reached a recommended phase 2 dose of trabectedin 1.0 mg/m² over 1 hour on day 1 and irinotecan 25 mg/m² on days 2 and 4 of a 21-day cycle. This regimen wasn’t chosen arbitrarily—it’s rooted in preclinical findings showing that trabectedin, above a certain concentration, can reverse the activity of the EWS::FLI1 fusion protein, the very engine driving Ewing sarcoma cell survival. What makes this approach particularly compelling is that low-dose irinotecan appears to potentiate this effect, creating a synergistic hit against the cancer’s core dependency. In the phase 2 portion of the study, the objective response rate was 33%, increasing to 39% when including patients from the phase 1 portion who received the recommended dose. Even more telling, the 6-month progression-free survival rate hit 48%—a meaningful benchmark in a disease where relapse often brings limited options.

What stood out beyond the headline numbers was the translational depth. Researchers didn’t just measure tumor shrinkage; they used 18F-FLT PET scans to assess early metabolic response and conducted transcriptional profiling that demonstrated reversal of the EWS::FLI1 transcriptome in tumor samples from a subset of patients. This kind of molecular confirmation—seeing the treatment hit its intended target at the genetic level—is what separates hopeful signals from substantiated progress. It also aligns with Seattle’s long-standing strength in bridging laboratory discovery with clinical application, a tradition anchored by institutions that have consistently turned mechanistic insights into tangible patient benefits.

Speaking of which, any conversation about advancing sarcoma care in the Pacific Northwest has to acknowledge the Fred Hutchinson Cancer Center. As a National Cancer Institute-designated comprehensive cancer center, Fred Hutch has been instrumental in sarcoma research for decades, running clinical trials that explore novel combinations and biomarkers. Their work in pediatric and young adult oncology—where Ewing sarcoma disproportionately strikes—means they’re not just participants in trials like SARC037; they’re often helping design them. Similarly, Seattle Children’s Hospital, with its nationally ranked oncology program, provides critical infrastructure for delivering complex regimens like trabectedin-irinotecan to adolescent patients, complete with specialized nursing, pharmacy support, and long-term follow-up protocols essential for monitoring both efficacy and late effects.

Then there’s the University of Washington School of Medicine, whose Department of Medicine and Division of Medical Oncology contribute both clinical expertise and investigative rigor to sarcoma-focused research. UW Medicine’s affiliation with the Seattle Cancer Care Alliance (SCCA) creates a seamless pathway where patients diagnosed at community hospitals can access cutting-edge trials and multidisciplinary sarcoma tumor boards. These boards—comprising medical oncologists, orthopedic oncologists, pathologists, radiologists, and genetic counselors—ensure that treatment decisions aren’t made in isolation but are informed by the full spectrum of disease biology and patient context. For a cancer as molecularly defined as Ewing sarcoma, where the EWS::FLI1 fusion is present in nearly all cases, this level of coordinated, biomarker-aware care isn’t just ideal—it’s becoming the standard of care that trials like SARC037 help validate.

Of course, progress in oncology isn’t measured solely in response rates or PFS curves. There’s a human dimension that often gets lost in the statistics—the fatigue from myelosuppression, the liver enzyme elevations noted as grade 3 or higher toxicities in over 15% of patients at the RP2D, the logistical burden of frequent infusions and scans. That’s where Seattle’s broader ecosystem of support comes into play. Organizations like Cancer Lifeline, which offers free emotional support, wellness classes, and resource navigation specifically tailored to cancer patients in Western Washington, develop into indispensable. So does the Mary Bridge Children’s Hospital Foundation in Tacoma, which, while slightly south, serves many families from across the region and provides critical financial and psychosocial aid for pediatric cancer journeys. These aren’t ancillary services; they’re part of the treatment architecture.

Given my background in biomedical journalism and public health storytelling, if this trend of molecularly targeted combinations impacts you or someone you love in the Seattle area, here are the three types of local professionals you’ll want to connect with—not as prescriptions, but as starting points for informed conversations:

• Sarcoma-Specialized Medical Oncologists: Look for physicians who dedicate a significant portion of their practice to soft tissue and bone sarcomas, ideally those affiliated with major cancer centers like Fred Hutch or SCCA. Key criteria include participation in cooperative group trials (such as those run by the Children’s Oncology Group or NRG Oncology), experience managing trabectedin-based regimens, and access to molecular profiling that can confirm EWS::FLI1 status or detect emerging resistance patterns.
• Pediatric and Adolescent Oncology Nurses with Infusion Therapy Expertise: Since regimens like trabectedin-irintecan require precise scheduling (day 1 infusion, followed by doses on days 2 and 4), nurses who specialize in administering complex chemotherapies and managing associated toxicities are vital. Seek out those with certifications in oncology nursing (OCN®) and proven experience in outpatient infusion centers that prioritize patient education—especially around recognizing early signs of hepatotoxicity or neutropenia.
• Genetic Counselors with Solid Tumor Oncology Focus: While Ewing sarcoma’s defining EWS::FLI1 fusion is typically somatic, genetic counselors play a growing role in clarifying somatic vs. Germline implications, facilitating tumor DNA sequencing, and helping families understand how molecular profiling results (like those from the SARC037 trial’s correlative studies) might influence treatment eligibility or clinical trial access. Look for counselors embedded in sarcoma multidisciplinary teams who can translate complex genomic reports into actionable insights.

Ready to find trusted professionals? Browse our complete directory of top-rated sarcoma specialists in the Seattle, WA area today.